{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:39:45Z","timestamp":1767836385100,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and intractable chronic disease. Glucocorticoids are the mainstay of treatment for EGPA. The drugs that target interleukin (IL)-5 signaling have also been marketed or developed in recent years. While no animal model can completely recapitulate EGPA, the ovalbumin (OVA)-induced eosinophilic vasculitis mouse model exhibits pathological similarities in the lungs. However, the effect of an anti-IL-5 drug has not yet been investigated using this model. This study used the OVA-induced eosinophilic vasculitis model to evaluate and characterize its usefulness, focusing on the effects of an anti-IL-5 antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Female C57BL\/6NCrSlc mice were intraperitoneally immunized on days 0 and 14 with OVA adsorbed onto an aluminum gel. From days 26\u201332, the mice were exposed to aerosolized 1% OVA daily for 1\u00a0h. Anti-IL-5 antibody or vehicle was injected intravenously or intraperitoneally once on the first day of aerosol exposure (day 26). On day 33, the eosinophil and lymphocyte counts in the blood and bronchoalveolar lavage fluid (BALF) were measured. Lung specimens were used to assess the vascular lesions formed in the pulmonary arteries. Plasma cytokine levels were measured on day 28.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The anti-IL-5 antibody significantly reduced eosinophil counts in the blood and BALF. In contrast, it did not inhibit the lymphocyte counts in BALF or vascular lesion formation. The anti-IL-5 antibody significantly blocked the plasma level of IL-5 on day 28. However, the levels of other cytokines (i.e., IL-2, IL-6, tumor necrosis factor-\u03b1, granulocyte-macrophage colony-stimulating factor, interferon-\u03b3, IL-12, IL-4, IL-13, and IL-17) were not altered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the investigated model, lymphocyte infiltration in lung tissue and cytokines other than or in addition to IL-5 were suggested to have contributed to the development of vasculitis. IL-5 signaling has a potential impact on EGPA pathogenesis via a different mechanism or in addition to the mechanism demonstrated in the OVA-induced eosinophilic vasculitis mouse model. The model may be useful for drug discovery targeting both eosinophilic and non-eosinophilic aspects of EGPA pathogenesis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1546785","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:07:36Z","timestamp":1742368056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of anti-interleukin-5 antibody on development of vasculitis in an ovalbumin-induced eosinophilic vasculitis mouse model"],"prefix":"10.3389","volume":"16","author":[{"given":"Kiyoto","family":"Kageyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102737","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11882-012-0290-3","article-title":"Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer","volume":"12","author":"Amini-Vaughan","year":"2012","journal-title":"Curr. Allergy Asthma Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1183\/09031936.03.00027302","article-title":"Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions","volume":"21","author":"B\u00fcttner","year":"2003","journal-title":"Eur. Respir. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B5","unstructured":"Assessment report\n          \n          \n          2016"},{"key":"B6","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"B7","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000024215","article-title":"Role of IL-5 in the development of allergen-induced airway hyperresponsiveness","volume":"120","author":"Hamelmann","year":"1999","journal-title":"Int. Arch. Allergy Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2332\/allergolint.13-OA-0679","article-title":"Rapamycin attenuates pulmonary allergic vasculitis in murine model by reducing TGF-\u03b2 production in the lung","volume":"63","author":"Koizumi","year":"2014","journal-title":"Allergol. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e143366","DOI":"10.1172\/jci.insight.143366","article-title":"A role for IL-33-activated ILC2s in eosinophilic vasculitis","volume":"6","author":"Kotas","year":"2021","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/JTS.1000355","article-title":"Tofacitinib suppressed remodeling of pulmonary eosinophilic vasculitis in a murine model","volume":"6","author":"Matsumoto","year":"2019","journal-title":"J. Transl. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/01902148.2016.1157226","article-title":"A phosphatidylinositol 3-kinase inhibitor strongly suppressed pulmonary vascular remodeling of allergic vasculitis in a murine model","volume":"42","author":"Oikawa","year":"2016","journal-title":"Exp. Lung Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3899\/jrheum.190093","article-title":"Evaluation of potential serum biomarkers of disease activity in diverse forms of vasculitis","volume":"47","author":"Rodriguez-Pla","year":"2020","journal-title":"J. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/1756-185X.12075","article-title":"Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model","volume":"16","author":"Suzuki","year":"2013","journal-title":"Int. J. Rheum. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2183\/pjab.87.463","article-title":"Interleukin-5 and IL-5 receptor in health and diseases","volume":"87","author":"Takatsu","year":"2011","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"B20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/01902140903360353","article-title":"Analysis of pulmonary allergic vasculitis with eosinophil infiltration in asthma model of mice","volume":"36","author":"Yamauchi","year":"2010","journal-title":"Exp. Lung Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1546785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:07:38Z","timestamp":1742368058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1546785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":23,"alternative-id":["10.3389\/fphar.2025.1546785"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1546785","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"article-number":"1546785"}}